MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Revenue 2011-2026 | TMO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.6 B | 42.9 B | 42.9 B | 44.9 B | 39.2 B | 32.2 B | 25.5 B | 24.4 B | 20.9 B | 18.3 B | 17 B | 16.9 B | 13.1 B | 12.5 B | 11.7 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.9 B | 11.7 B | 27.1 B |
Quarterly Revenue Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.1 B | 10.9 B | 10.4 B | 10.6 B | 10.5 B | 10.3 B | 10.6 B | 10.7 B | 10.7 B | - | 10.7 B | 11 B | 11.8 B | - | 9.33 B | 9.27 B | 9.91 B | - | 8.52 B | 6.92 B | 6.23 B | 6.83 B | 6.27 B | 6.32 B | 6.12 B | 6.51 B | 5.92 B | 6.08 B | 5.85 B | 6.05 B | 5.12 B | 4.99 B | 4.76 B | 4.95 B | 4.49 B | 4.54 B | 4.29 B | 4.65 B | 4.12 B | 4.27 B | 3.92 B | 4.49 B | 4.17 B | 4.32 B | 3.9 B | 3.47 B | 3.19 B | 3.24 B | 3.19 B | 3.26 B | 3.09 B | 3.11 B | 3.06 B | 3.09 B | 2.93 B | 2.85 B | 2.72 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 B | 2.72 B | 6.29 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
6.32 B | $ 113.86 | -0.85 % | $ 34.6 B |  USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 190.59 | -0.8 % | $ 136 B | USA |
 |
DexCom
DXCM
|
4.66 B | $ 63.64 | 0.68 % | $ 24.8 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 16.32 | -0.61 % | $ 493 M | USA |
 |
Guardant Health
GH
|
982 M | $ 90.59 | 1.04 % | $ 11.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 107.81 | -1.66 % | $ 8.89 B |  Irlanda |
 |
Illumina
ILMN
|
4.37 B | $ 127.23 | -0.4 % | $ 20.2 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.63 | -1.07 % | $ 939 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 274.85 | 0.14 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 75.68 | -0.28 % | $ 5.11 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 493.63 | -0.48 % | $ 14.2 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 16.99 | 4.23 % | $ 176 M |  China |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.62 | -1.07 % | $ 428 M | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 7.98 | -0.5 % | $ 1.02 B | USA |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.93 | 3.82 % | $ 2.15 B | USA |
 |
Natera
NTRA
|
820 M | $ 207.69 | 1.38 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.4 | -1.76 % | $ 420 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
24 M | $ 26.0 | 0.08 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 6.21 | -5.57 % | $ 368 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 167.8 | -0.25 % | $ 8.32 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 14.86 | -0.1 % | $ 4.22 B | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 24.96 | 0.93 % | $ 693 M | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.6 | -9.09 % | $ 106 M | USA |
|
Biodesix
BDSX
|
71.3 M | $ 14.71 | -4.21 % | $ 1.91 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.99 | -0.79 % | $ 20 B |  Niderland |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.61 | -1.34 % | $ 61.9 M | Irlanda |
 |
VolitionRx Limited
VNRX
|
1.73 M | $ 0.17 | -0.89 % | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
932 M | $ 301.9 | -0.72 % | $ 18 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.08 | -4.13 % | $ 4.78 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 2.02 | 2.54 % | $ 8.94 M | USA |